Juvenescence

LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.

Morphoceuticals is a biotechnology platform dedicated to advancing limb regeneration and regenerative medicine. The company focuses on understanding the biophysical mechanisms that guide decision-making in complex pattern regulation. By utilizing bioelectric dynamics, multi-omics, and artificial intelligence, Morphoceuticals aims to manipulate bioelectric signals to enhance developmental patterning and stimulate regeneration in organisms that typically do not regenerate tissues or organs. Its work supports medical researchers in addressing challenging health conditions, improving the health of amputation stumps, promoting organ regeneration, and treating channelopathies. Through these innovative approaches, Morphoceuticals seeks to contribute significantly to the fields of tissue repair and regenerative interventions.

MDI Therapeutics is a discovery stage pharmaceutical company focused on developing innovative therapies for fibrotic diseases and fibroproliferative disorders. The company utilizes a proprietary discovery platform to identify novel small molecule and protein drug candidates. These candidates undergo key translational experiments involving clinical biomarkers to assess their effectiveness. MDI Therapeutics aims to enable healthcare providers to prevent fibrosis and potentially reverse the fibrotic disease process, addressing significant unmet medical needs in this area.

Portage Pharmaceuticals LTD. is developing innovative cell permeable peptide (CPP) therapies to normalize gene expression, restore protein function, and improve medical outcomes. The Company has spun out its lead asset, PPL-003, to ophthalmic indications and has licensed this CellPorter technology to EyGen, a new ophthalmic company.

LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.

LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.

Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.

BYOMass is developing therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses.

BHB Therapeutics is developing novel approaches to induce a state of ketosis, which may have protective effects against age-related disease.

AgeX Therapeutics is a biotechnology company dedicated to developing innovative therapeutics aimed at addressing human aging and degenerative diseases. Based in Alameda, California, the company focuses on harnessing proprietary technologies, such as telomerase-mediated cell immortality and induced Tissue Regeneration (iTR), to create treatments for age-related conditions. Its primary product pipeline includes two cell-based therapies: AGEX-BAT1, designed to treat age-related metabolic disorders like Type II diabetes, and AGEX-VASC1, which aims to restore vascular support in ischemic tissues. Additionally, AgeX is advancing AGEX-iTR1547, a drug-based formulation intended to enhance regenerative potential in aged tissues affected by degenerative diseases. The company also markets human embryonic stem cells and offers tools for genomic interpretation through the GeneCards Database Suite. AgeX Therapeutics collaborates with academic institutions, including a research program with the University of California, Irvine, focusing on neural stem cells for Huntington's disease and other neurological disorders. Founded in 2017, AgeX continues to explore novel solutions for aging-related challenges.

Napa Therapeutics is a biotechnology company focused on a novel target linked to one of the fundamental processes of aging. A privately held British Virgin Islands company with an office in the Isle of Man, Napa is developing small molecule drugs to address this target.

FoxBio is a developer of a small molecules techniques intended to reduce senescent cells in human bodies. The company's techniques targets the pro-survival pathways of senescent cells to remove them from the body, enabling patients to have multiple health benefits and delay the onset of age related diseases.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

AgeX Therapeutics is a biotechnology company dedicated to developing innovative therapeutics aimed at addressing human aging and degenerative diseases. Based in Alameda, California, the company focuses on harnessing proprietary technologies, such as telomerase-mediated cell immortality and induced Tissue Regeneration (iTR), to create treatments for age-related conditions. Its primary product pipeline includes two cell-based therapies: AGEX-BAT1, designed to treat age-related metabolic disorders like Type II diabetes, and AGEX-VASC1, which aims to restore vascular support in ischemic tissues. Additionally, AgeX is advancing AGEX-iTR1547, a drug-based formulation intended to enhance regenerative potential in aged tissues affected by degenerative diseases. The company also markets human embryonic stem cells and offers tools for genomic interpretation through the GeneCards Database Suite. AgeX Therapeutics collaborates with academic institutions, including a research program with the University of California, Irvine, focusing on neural stem cells for Huntington's disease and other neurological disorders. Founded in 2017, AgeX continues to explore novel solutions for aging-related challenges.

LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.